Schizophrenia Genomics: Convergence on Synaptic Development, Adult Synaptic Plasticity, or Both?

Jeremy Hall and Nicholas J. Bray

ABSTRACT

Large-scale genomic studies of schizophrenia have identified hundreds of genetic loci conferring risk to the disorder. This progress offers an important route toward defining the biological basis of the condition and potentially developing new treatments. In this review, we discuss insights from recent genome-wide association study, copy number variant, and exome sequencing analyses of schizophrenia, together with functional genomics data from the pre- and postnatal brain, in relation to synaptic development and function. These data provide strong support for the view that synaptic dysfunction within glutamatergic and GABAergic (gamma-aminobutyric acidergic) neurons of the cerebral cortex, hippocampus, and other limbic structures is a central component of schizophrenia pathophysiology. Implicated genes and functional genomic data suggest that disturbances in synaptic connectivity associated with susceptibility to schizophrenia begin in utero but continue throughout development, with some alleles conferring risk to the disorder through direct effects on synaptic function in adulthood. This model implies that novel interventions for schizophrenia could include broad preventive approaches aimed at enhancing synaptic health during development as well as more targeted treatments aimed at correcting synaptic function in affected adults.

https://doi.org/10.1016/j.biopsych.2021.10.018

The synapse is the principal means of neuronal communication and therefore central to all brain functions, with more than 160 trillion synapses estimated in the human cerebral cortex alone (1). Unsurprisingly, postulated disturbances in synaptic function and connectivity have figured prominently in neurobiological theories of schizophrenia (2–10), supported by neuropathological (11,12), neuropharmacological (13,14), and genomic (15) studies. Two recent landmark genomic studies of schizophrenia (16,17) provide further evidence for a synaptic component to the condition and bring into sharper focus some of the genes that are etiologically relevant. In the following review, we discuss these and other genomic insights into schizophrenia susceptibility in the context of gene expression and synaptic function in the developing and adult brain.

SYNAPTIC GENES AND GENETIC RISK FOR SCHIZOPHRENIA

Advances in genotyping and sequencing technology combined with large sample sizes have led to the identification of robust genetic associations with schizophrenia over the past decade. These have revealed a complex polygenic architecture for the disorder, involving numerous common (>1% population frequency) genetic susceptibility variants of individually low penetrance as well as rarer genetic variants that can have stronger effects on schizophrenia risk (18) (Figure 1).

Genome-wide association studies (GWASs) test association between a trait and more than a million common genetic variants spanning the human genome. A great advantage of GWASs over earlier candidate gene association studies is that they are agnostic in design, requiring no prior knowledge of pathophysiology or of the genes that might be involved. However, this comes at a cost of a huge multiple-testing penalty (the accepted threshold for genome-wide significance in GWASs is $p < 5 \times 10^{-8}$), and therefore, very large sample sizes are required to confidently detect common risk variants of the effect sizes generally observed for schizophrenia (common variant odds ratios typically <1.1). The most recent schizophrenia GWAS of the international Psychiatric Genomics Consortium (PGC) meta-analyzed genotyping data from approximately 70,000 people with schizophrenia and approximately 240,000 unaffected control subjects, identifying more than 250 common genetic loci associated with the disorder at genome-wide significance (16). Although it is difficult to confidently identify the relevant genes at individual GWAS loci (owing to often broad regions of genetic association, the predominantly noncoding nature of common risk alleles, and the potential for long-range gene regulation (19), genetic associations were found to be significantly enriched within genes belonging to Gene Ontology sets relating to the synapse, ion channels, or neurodevelopment (16).

Studies of rare genetic variation have also highlighted an important role for synaptic genes in schizophrenia susceptibility. Copy number variants (CNVs) are large deletions or duplications that can result in loss or gain of genic sequence. In the largest CNV study of schizophrenia to date (20), rare (<1%
population frequency) deletions identified in schizophrenia were found to disproportionately affect genes relating to synaptic function, with the Gene Ontology term “synaptic” and the activity-regulated cytoskeleton protein complex [as defined by Kirov et al. (21)] ranked first for statistical significance and effect size, respectively. In addition, the meta-analysis identified 8 individual CNV loci associated with schizophrenia at genome-wide significance. While schizophrenia-associated CNVs at most of these loci encompass multiple genes, they also include deletions that specifically disrupt NRXN1, encoding the synaptic cell-adhesion protein neurexin-1, which have an estimated odds ratio of approximately 14 (20).

Exome sequencing allows identification of rare protein-damaging coding genetic variants at single-nucleotide resolution. Such analyses have highlighted an excess of loss-of-function and missense genetic variants in genes encoding synaptic proteins involved in the NMDA receptor complex and postsynaptic density as well as voltage-gated calcium channels in schizophrenia (17,22–24). In the recent large-scale study of the Schizophrenia Exome Meta-Analysis (SCHEMA) Consortium based on data from more than 24,000 schizophrenia cases and 97,000 control subjects, 10 genes were found to contain an exome-wide significant excess of ultrarare protein-damaging coding mutations in schizophrenia (17). These include a gene encoding an NMDA receptor subunit that is also implicated in common genetic risk for schizophrenia through GWAS fine-mapping (GRIN2A; estimated odds ratio for highly damaging coding variants ≈24.1), a gene encoding a glutamatergic AMPA receptor subunit (GRIA3; estimated odds ratio for highly damaging coding variants ≈20.1), and a gene encoding a synaptic voltage-gated calcium channel (CACNA1G; estimated odds ratio for highly damaging coding variants ≈4.25).

Thus, both common and rare variant genomic studies implicate genes that are directly involved in synaptic activity and plasticity in risk for schizophrenia (15–17). However, these synaptic processes are important in shaping neural circuits during development as well as for mature brain function (10). Gene set enrichment analyses, although implicating synaptic biology in schizophrenia, are currently limited by our incomplete understanding of gene function and do not necessarily inform as to the developmental timing of the risk mechanisms. In addition, and as we discuss later, several genes implicated in schizophrenia through genomic studies have reported roles in early synapse formation. This raises the question of at which stage(s) of development do synaptic disturbances confer susceptibility to the disorder.

**THE NEURODEVELOPMENTAL HYPOTHESIS OF SCHIZOPHRENIA**

One of the most influential theories of the etiology of schizophrenia, first expounded in the 1980s (25,26), holds that the condition has its fundamental origins in early (prenatal) brain development. A key source of evidence supporting the neurodevelopmental hypothesis of schizophrenia comes from epidemiological studies. A number of early-life insults have been shown to increase risk for the condition, including prenatal infections, obstetric complications, and maternal famine/nutritional deficiency during pregnancy (27).

Large-scale longitudinal cohort studies have provided evidence that people who later develop schizophrenia have, on average, subtle impairments of cognition, behavior, and development in their childhood years relative to expectations (28,29). The presence of gross neuroanatomical deviations (e.g., ventricular enlargement) at schizophrenia onset and a general absence of markers of neurodegeneration are further cited as support for a neurodevelopmental model of the disorder (30).

The neurodevelopmental hypothesis acknowledges that notwithstanding the subtle premorbid deficits outlined above, the pre- or perinatal component of schizophrenia does not generally manifest as overt psychosis until late adolescence. Indeed, it is difficult to predict who will develop schizophrenia even when dealing with high-risk groups at the period of greatest risk of transition to the disorder (31). To account for the delayed manifestation of the illness, the classic neurodevelopmental model holds that the effects of early insults on the developing brain are only fully revealed when the brain matures in early adulthood (consequent on, for example, synaptic pruning and myelination of the frontal cortex). Support for this view is provided by animal studies showing that effects of neonatal hippocampal lesions on schizophrenia-relevant...
pheno\text{top}t\text{es}, \text{such as sensori}\text{motor gating d}\text{eficits and sensi}\text{tivity to stress, can remain latent until m}\text{aturity} (32,33).

**FUNCTIONAL GENOMIC SUPPORT FOR AN EARLY NEURODEVELOPMENTAL COMPONENT TO SCHIZOPHRENIA**

Functional genomic studies provide strong support for a pre\text{n}atal component to schizophrenia (34). For example, Gulsuner \text{et \text{al.} (35)} found that genes containing damaging de novo mutations in the disorder were most significantly coexpressed in the frontal cortex during fetal development rather than during childhood and adolescence/adulthood. Similarly, Clifton \text{et \text{al.} (36)} found that common variant genetic association with schizophrenia was positively correlated with relative expression of the corresponding genes in the prefrontal cortex during the second trimester of gestation and early infancy. Moreover, common risk variants for schizophrenia are significantly overrepresented within genetic variants affecting DNA methylation (methylation quantitative trait loci) (37), gene expression (expression quantitative trait loci) (eQTL) (38,39), and gene splicing (splicing quantitative trait loci) (40) in the human fetal brain, indicating likely mechanisms by which they operate.

**EARLY SYNAPTIC CONNECTIVITY AND GENETIC RISK FOR SCHIZOPHRENIA**

The establishment of synaptic connectivity in the human cerebral cortex begins in the second trimester of gestation, as differentiating neurons that have migrated to their target destination start to extend axons and dendrites. This is followed by a period of intense synaptogenesis during the third trimester of pregnancy that continues into early childhood (40–42). There is now good evidence that at least some of the genetic risk factors for schizophrenia operating in the fetal brain directly affect the establishment of synaptic connectivity. For example, \text*{NRXN1*, which is most highly expressed in late gestation and early childhood (43) and is a target of schizophrenia-associated CNVs (20), appears to serve a role in synapse formation (44,45). Of the 10 genes found to harbor an exome-wide significant excess of rare damaging coding mutations in schizophrenia in the SCHEMA Consortium analysis (17), TRIO is known to play an important role in developmental neurite outgrowth (46), while Set\text{d}1a haploinsufficiency in mice has been reported to reduce axonal branching (47) and SP4 knockdown to affect dendritic branching (48) during development. The recent PGC GWAS (16) included fine-mapping of schizophrenia-associated single nucleotide polymorphisms to several individual genes with known roles in neurite outgrowth and synapse formation, including \text*{ZNF804A (49), in which schizophrenia risk variation may act specifically during fetal brain development (50,51); CNTN4 (52); LRRCA4 (53); and DCC (54), the last encoding a Netrin-1 receptor known to interact with TRIO (46). In addition, studies that integrate schizophrenia GWAS data with eQTL/splicing quantitative trait loci operating in the human fetal brain provide evidence for altered prenatal regulation of several genes involved in neurite outgrowth in association with genetic risk for the condition, including CNTN4 (39,52) and genes within the protocadherin alpha cluster (55,56). These findings suggest that synaptic disturbances conferring risk for schizophrenia begin in utero. However, the expression of several of these molecules persists throughout postnatal brain development (57), when they may additionally contribute to synaptic maturation in response to environmental stimuli (10) and adult synaptic function.

**FUNCTIONAL GENOMIC SUPPORT FOR SCHIZOPHRENIA RISK MECHANISMS OPERATING IN THE ADULT BRAIN**

Common genetic risk variants for schizophrenia are enriched for eQTL operating in the adult (58,59) as well as fetal (38,39) human brain, and many of the associated prenatal genetic effects on gene expression continue into adulthood (16,38,39,55,60). Schizophrenia associations are significantly overrepresented in genes with high relative specificity of expression in several regions of the adult human brain compared with other tissues, including the cerebral cortex, nucleus accumbens, hippocampus, amygdala, caudate, and cerebellum (16). Notably, in the adult human brain, schizophrenia single nucleotide polymorphism heritability is concentrated in regulatory genomic sites operating in neurons rather than glia (61,62). Indeed, schizophrenia associations are reported to be enriched within genes that show high specificity of expression in neurons from the cerebral cortex (pyramidal neurons and interneurons) and hippocampus (pyramidal and granule neurons) of the adult human brain (16) and additionally within genes with high specificity of expression in medium spiny neurons of the striatum in the more extensive single-cell datasets from adult mouse brain (16,63). These data suggest that genomic risk for schizophrenia is partly determined by neuron-specific processes operating in the mature brain, of which synaptic plasticity is a prime example.

**ADULT SYNAPTIC PLASTICITY AND GENETIC RISK FOR SCHIZOPHRENIA**

Synaptic plasticity is the property by which neurons modulate the strength of synaptic transmission and connectivity in response to activity and is thought to be the biological basis of associative learning and memory (64,65), abnormalities in which have been implicated in schizophrenia symptomatology (7,8). As discussed in an earlier review (15), findings from rare variant studies of schizophrenia show significant convergence on molecular pathways involved in synaptic plasticity. Both the glutamatergic NMDA receptor complex and voltage-gated calcium channels, which are strongly implicated in genetic risk for schizophrenia (15), play a central role in synaptic plasticity by allowing entry of Ca\textsuperscript{2+} into postsynaptic dendrites (66,67). This in turn activates second messenger systems that result in changes in synaptic efficiency through incorporation of glutamatergic AMPA receptors into the postsynaptic membrane and changes in the size and shape of dendritic spines.

The recent schizophrenia GWAS of the PGC (16) and the exome sequencing analysis of the SCHEMA Consortium (17) provide further evidence for the involvement of synaptic plasticity and adult memory processes in risk for schizophrenia. Indeed, \text*{GRIN2A and SP4, 2 genes implicated in schizophrenia susceptibility through both fine-mapping of GWAS loci (16) and exome sequencing (17), have direct roles in NMDA receptor function and associative memory. GRIN2A encodes the
GluN2A subunit of the NMDA receptor. Unlike the other major GluN2 subunit, GluN2B, GluN2A is expressed predominantly postnatally, reaching maximal expression in adolescence (67,68). Prominent GluN2A expression is observed in the hippocampus (68,69), and hippocampal memory deficits are observed after adult GluN2A antagonism (70) and Grin2a knockout (71) in rodents. SP4 encodes a transcription factor known to regulate NMDA receptor subunit expression (72,73). Although SP4 expression is highest in the prenatal brain (67), it appears to play an important role in the adult hippocampus, with Sp4 hypomorphic mice displaying deficits in hippocampal learning that could be rescued by restoration of Sp4 function (74). Other genes with known roles in adult synaptic function implicated in schizophrenia by the SCHEMA exome sequencing analysis (17) are GRIA3, encoding the AMPA receptor subunit 3 (75), and CACNA1G, encoding the Cav3.1 channel (76,77), while such genes prioritized by fine-mapping schizophrenia-associated loci in the recent PGCG GWAS (16) include GRM1 (78), GABBR2 (79), CLCN3 (80), and CACNA1C (81). Recent transcriptome-wide association studies of schizophrenia based on eQTL identified in adult human brain provide evidence for altered expression of several synaptic plasticity genes in association with genetic risk for schizophrenia, including CLCN3 (80), GABRA2 (82), and LRPR (83) in the adult frontal cortex (60) and GRM3 (84) and CACNA1C (81) in the adult dentate gyrus (85).

Schizophrenia-associated genes encoding molecules involved in neuirite and synaptic development may also exert an effect on synaptic activity and remodeling in the adult human brain. For example, NRXN1 is reported to increase Ca²⁺ influx through the NMDA receptor (86) and its splicing to affect the stability of hippocampal fear memories (87), while TRIO has been shown to support glutamatergic transmission and long-term potentiation in rodent hippocampal slice cultures (88). We believe that a systematic assessment of the role of well-supported schizophrenia susceptibility genes in both synaptic development and adult synaptic function is now warranted, with genes implicated through exome sequencing and fine-mapping of nonsynonymous coding variants prioritized and with due attention to the specific RNA transcripts affected by genetic risk variation. Here, use of age-specific gene knockout strategies and advanced in vitro models (e.g., brain organoids) are likely to be informative.

Although functional genomic data provide evidence for adult neuronal mechanisms in schizophrenia susceptibility, genetic enrichment studies based on gene expression in the postmortem brain might underestimate the role of schizophrenia risk genes in adult synaptic plasticity. This is because activity-related changes in gene expression, arising within specific neuronal circuits at particular points in time, are unlikely to be reliably captured in postmortem tissues. This contrasts with early brain development, when large gene expression programs are playing out en masse. The integration of human genomic findings with data from in vivo and in vitro model systems provides one means of assessing the role of activity-dependent gene expression in schizophrenia susceptibility. For example, Clifton et al. (89) found that genes with increased expression in the CA1 region of the rodent hippocampus after specific forms of associative learning were enriched for genes affected by CNVs in schizophrenia. Similarly, Roussos et al. (90) reported enrichment of common genetic risk variants for schizophrenia within a transcriptional gene network associated with depolarization of neurons derived from human induced pluripotent stem cells. Understanding how schizophrenia risk variation affects processes involved in adult synaptic plasticity is a key ongoing research question, which may have direct relevance to the development of new treatments.

SYNAPTIC DYSFUNCTION AS BOTH A NEURODEVELOPMENTAL ANTECEDENT AND AN ONGOING RISK MECHANISM FOR SCHIZOPHRENIA

The aforementioned suggests a model in which genetic risk for schizophrenia operates not only on the formation and maintenance of synaptic networks during brain development but also through direct effects on synaptic function and plasticity in the adult brain. This is supported by the findings of a recent study indicating that pronounced enrichment of common genetic risk variation for schizophrenia was found in human brain gene coexpression modules involved in synaptic transmission and neuronal excitability that are maintained, or increased, in expression from birth into adulthood (91). Such a model is also consistent with key aspects of several other neurobiological theories of schizophrenia based on epidemiological, neuropathological, neuroimaging, neuropharmacological, and cognitive findings (2–10).

In keeping with the classic neurodevelopmental hypothesis (25,26), genetic and functional genomic studies support the notion that schizophrenia pathogenesis begins in utero. As we have noted, several of the genes that are strongly implicated in schizophrenia risk through exome sequencing and fine-mapping of GWAS loci have known roles in neurite outgrowth and synaptogenesis, suggesting that disturbances in the initial formation of synaptic connectivity are important for later expression of the condition. From birth, synaptic networks are shaped and refined by activity and experience, with up to half of synapses being eliminated through synaptic pruning and others being strengthened through synaptic maturation (41). Synaptic activity through the NMDA receptor appears to be essential for this postnatal development and refinement of excitatory connections (92,93). Differences in NMDA receptor activity through schizophrenia-associated genetic effects on GRIN2A is therefore likely to alter the maturation of relevant glutamatergic synapses and have a direct impact on synaptic plasticity throughout postnatal life. Developmental synaptic pruning, which in the frontal cortex extends into early adulthood (40,94), is a prime candidate for exposing and exacerbating compromised neuronal networks and has long been postulated as a schizophrenia risk mechanism in itself (2,4). Indeed, several groups have reported increased synaptic elimination with higher expression of complement C4/C4A (95–99), which is elevated in the human brain in association with schizophrenia risk variation at the C4A gene locus (38,99). Other gene variants may increase the risk for schizophrenia by affecting neuronal function primarily in the mature brain. For example, genes within the schizophrenia-associated Gene Ontology term of “voltage-gated calcium channel activity” display highest expression in the dorsolateral prefrontal cortex in adolescence and early adulthood (100). Figure 2 shows the...
developmental timing of various synaptic processes that appear relevant to schizophrenia genetic risk, with examples of implicated genes that have been reported to serve a role in these processes.

Convergent genetic evidence for GRIN2A as a schizophrenia susceptibility gene provides strong support for long-held (hypo-) glutamatergic theories of the disorder that were based on the observed induction of positive, negative, and cognitive symptoms in healthy adults after NMDA receptor antagonism (13,101). Although common genetic risk variation for schizophrenia is enriched within genes expressed across multiple regions of the adult human brain, there appears to be pronounced signal in genes with higher specificity for expression in the cerebral cortex and limbic structures (nucleus accumbens, amygdala, and hippocampus) (16). Synaptic disturbances in these regions of the adolescent and adult brain are likely to affect working memory, executive function, associative learning, and predictive learning processes that are hypothesized to be central to cognitive, motivational, and psychosomatic aspects of the disorder (7–9,102–104). The effects of genetic risk variants on adult synaptic plasticity may be particularly marked in the context of preexisting neurodevelopmental alterations in brain circuitry.

Risk for schizophrenia is not solely determined by genetics and, as noted above, a number of pre- and perinatal environmental exposures are also associated with later development of the condition (27). Both prenatal nutritional deficiency and obstetric complications have been shown to have an impact on the developing hippocampus, with later effects on cognition and behavior (105,106). Postnatal maturation and shaping of neuronal circuits is governed by activity and experience, mediated through synaptic plasticity mechanisms, with environmental enrichment found to increase dendritic spine density (107,108). Conversely, psychological stress, a precipitating factor for various neuropsychiatric disorders, is associated with volume reductions in the prefrontal cortex and hippocampus and has been reported to reduce dendritic spine density in these areas in rodents (109), while repeated exposure to Δ²-tetrahydrocannabinol, the main psychoactive ingredient in cannabis, might have an impact on schizophrenia risk through reported effects on hippocampal dendritic spine density and glutamate receptor subunit expression (110). There is evidence that some of these environmental factors have more potent effects on schizophrenia susceptibility in individuals of high genetic risk for the disorder (i.e., gene-environment interaction) (111,112).

SYNAPTIC DYSFUNCTION ACROSS THE NEUROPSYCHIATRIC SPECTRUM

Genetic evidence for disturbances in synaptic development and function is not confined to schizophrenia. For example, rare variants affecting genes involved in synaptic connectivity, including NRXN1, have been strongly implicated in autism (113), and common variants in or near genes encoding voltage-gated calcium channels (e.g., CACNA1C) are also associated with bipolar disorder (114). Indeed, a GWAS meta-analysis across 8 neuropsychiatric conditions (anorexia nervosa, attention-deficit/hyperactivity disorder, autism, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, and Tourette syndrome) found pleiotropic (shared) loci to be enriched for genes involved in glutamate receptor signaling and voltage-gated calcium channel complexes as well as genes involved in neural development (115). However, compared with schizophrenia, autism is associated with a higher burden of rare damaging variants (116) [which may additionally affect earlier neurodevelopmental processes, such as cell proliferation (117)], while bipolar disorder has a lower burden of rare CNVs (118–120). As argued by Owen et al. (121,122), evidence suggests that neuropsychiatric disorders reflect a gradient of early neurodevelopmental disturbance, with greater prenatal impacts in childhood-onset conditions, such as autism, than in schizophrenia, and with diagnoses such as bipolar disorder and major depression associated with less neurodevelopmental disruption still [although common risk variants for these latter conditions may still operate, albeit more subtly, in the prenatal brain (38,55,115,123,124)]. The extent of neurodevelopmental disturbance is also likely to explain some of the clinical heterogeneity in schizophrenia. For example, in the initial report of a genome-wide significant association between loss-of-function variants in SETD1A and schizophrenia (116), 7 of 10 people with schizophrenia carrying these mutations also had learning difficulties. A corollary is that in cases of schizophrenia when cognition is relatively spared, there may be less early developmental disruption. Improved linkage between genetic and clinical data might help refine the biological processes contributing to the diverse symptomatology and course of the disorder.

IMPLICATIONS FOR TREATMENT

The above model suggests two strategies for reducing the incidence of schizophrenia and its severity: first, a broad
preventive approach aimed at maximizing synaptic integrity during brain development, and second, focused treatments aimed at ameliorating deficits in synaptic function after the onset of psychosis. Given that prenatal brain development appears to be an important variable in later risk for schizophrenia, universal strategies for optimizing nutrition and maternal care during pregnancy could, if defined appropriately, be a cost-effective and feasible means of reducing the incidence of the disorder (125–127). In people who have already experienced a psychotic episode, targeted strategies based on restoring cortical and hippocampal synaptic function may be effective in treating cognitive and other symptoms of the condition. Indeed, there is encouraging evidence from randomized, placebo-controlled trials that augmentation of typical antipsychotic treatment with agonists of the glycine site of the NMDA receptor reduces both positive and negative symptoms in patients with schizophrenia (128). Current large-scale genomic studies of schizophrenia may suggest further targets for drug development (129).

CONCLUSIONS
Both common and rare variant genomic analyses provide strong support for a synaptic component to schizophrenia etiology, consistent with a number of long-standing neurobiological theories of the disorder. Implicated genes and functional genomic data suggest that synaptic disturbances begin in utero but continue throughout development, with some alleles conferring risk for schizophrenia through direct effects on synaptic function in adulthood. However, a more precise understanding of synaptic processes contributing to the disorder will require elucidation of the particular gene transcripts that are affected by genetic risk variation and the cellular specificity of these effects, together with a systematic investigation of their role in synaptic development and function in relevant cell types and models. With advances in RNA sequencing, single-cell technologies, in vitro models, and genome editing, such investigations are already becoming possible. It is hoped that the insights provided will pave the way for improved treatments for schizophrenia, which might even include strategies to prevent its onset.

ACKNOWLEDGMENTS AND DISCLOSURES
This study was supported by grants (Grant No. MR/R011397/1 [to JH]) and (Grant No. MR/T002379/1 [to NJB]) and a Centre grant (Grant No. MR/ L010305/1) from the Medical Research Council (United Kingdom). We thank Dr. Darren Cameron for creating Figure 1.

JH and NJB have received a research award from Takeda Pharmaceutical Company Ltd.

ARTICLE INFORMATION
From the MRC Centre for Neuropsychiatric Genetics & Genomics, Division of Psychological Medicine & Clinical Neurosciences; and the Neuroscience & Mental Health Research Institute, Cardiff University, Cardiff, United Kingdom.

Address correspondence to Jeremy Hall, Ph.D., at HallJ10@Cardiff.ac.uk or Nicholas J. Bray, Ph.D., at BrayN30@Cardiff.ac.uk.

Received May 10, 2021; revised Oct 22, 2021; accepted Oct 23, 2021.

REFERENCES
1. Tang Y, Nyengaard JR, De Groot DM, Gandersen HJ (2001): Total regional and global number of synapses in the human brain neocortex. Synapse 41:258–273.
2. Feinberg I (1982–): Schizophrenia: Caused by a fault in programmed synaptic elimination during adolescence? J Psychiatr Res 17:319–334.
3. Bullmore ET, Frangou S, Murray RM (1997): The dysplastic net hypothesis: An integration of developmental and dysconnectivity theories of schizophrenia. Schizophr Res 28:143–156.
4. Mcglashan TH, Hoffman RE (2000): Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch Gen Psychiatry 57:637–648.
5. Minnics K, Middleton FA, Lewis DA, Levitt P (2001): Analysis of complex brain disorders with gene expression microarrays: Schizophrenia as a disease of the synapse. Trends Neurosci 24:479–486.
6. Harrison PJ, Weinberger DR (2005): Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence [published corrections appear in Mol Psychiatry 2005; 10:420 and Mol Psychiatry 2005; 10:804]. Mol Psychiatry 10:40–58; image 5.
7. Hall J, Romanuik L, McIntosh AM, Steele JD, Johnstone EC, Lawrie SM (2009): Associative learning and the genetics of schizophrenia. Trends Neurosci 32:359–365.
8. Friston K, Brown HR, Siemekus J, Stephan KE (2016): The dysconnection hypothesis (2016), Schizophr Res 176:83–94.
9. Krystal JH, Antevic A, Yang GW, Dresler GS, Wester NG, Murray JD (2017): Impaired tuning of neural ensembles and the pathophysiology of schizophrenia: A translational and computational neuroscience perspective. Biol Psychiatry 81:647–655.
10. Forsyth JK, Lewis DA (2017): Mapping the consequences of impaired synaptic plasticity in schizophrenia through development: An integrative model for diverse clinical features, Trends Cogn Sci 21:760–778.
11. Harrison PJ (1999): The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 122:593–624.
12. Osimo EF, Beck K, Reis Marques T, Howes OD (2019): Synaptic loss in schizophrenia: A meta-analysis and systematic review of synaptic protein and mRNA measures. Mol Psychiatry 24:549–561.
13. Krystal JH, D’Souza DC, Mathalon D, Perry E, Belger A, Hoffman R (2003): NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: Toward a paradigm shift in medication development. Psychopharmacology (Berl) 169:215–233.
14. Breier A, Adler CM, Weisenfeld N, Su TP, Elman I, Picken L, et al. (1998): Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach. Synapse 29:142–147.
15. Hall J, Trent S, Thomas KL, O’Donovan MC, Owen MJ (2015): Genetic risk for schizophrenia: Convergence on synaptic pathways involved in plasticity. Biol Psychiatry 77:52–58.
16. The Schizophrenia Working Group of the Psychiatric Genomics Consortium, Ripke S, Walters JT, O’Donovan MC (2020): Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. medRxiv. https://doi.org/10.1101/2020.09.12.20192922.
17. Singh T, Neale BM, Daly MJ (2020): Exome sequencing identifies rare coding variants in 10 genes which confer substantial risk for schizophrenia. medRxiv. https://doi.org/10.1101/2020.09.18.20192815.
18. Smeland OB, Frei O, Dale AM, Andreassen OA (2020): The polygenic architecture of schizophrenia — Rethinking pathogenesis and nosology. Nat Rev Neurol 16:366–379.
19. Bray NJ, Hall MJ (2016): Translating genetic risk loci into molecular risk mechanisms for schizophrenia. Schizophr Bull 42:5–8.
20. Marshall CR, Howrigan DP, Merico D, Thiruvahindrapu B, Wu W, Greer DS, et al. (2017): Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects [published corrections appear in Nat Genet 2017; 49:651 and Nat Genet 2017; 49:1558]. Nat Genet 49:27–35.
21. Kirov G, Rocking NJ, Holmans P, Ivanov D, Ikeda M, Ruderfer D, et al. (2012): De novo CNV analysis implicates specific abnormalities
of post-synaptic signalling complexes in the pathogenesis of schizophrenia. Mol Psychiatry 17:142–153.

22. Fromer M, Pocklington AJ, Kavanagh DH, Williams HJ, Dywer S, Gormley P, et al. (2014): De novo mutations in schizophrenia implicate synaptic networks. Nature 506:179–184.

23. Purcell SM, Moran JL, Fromer M, Ruderfer D, Solovieff N, Rousso P, et al. (2014): A polygenic burden of rare disruptive mutations in schizophrenia. Nature 506:185–190.

24. Rees E, Carrera N, Morgan J, Hambridge K, Escott-Price V, Pocklington AJ, et al. (2019): Targeted sequencing of 10,198 samples confirms abnormalities in neuronal activity and implicates voltage-gated sodium channels in schizophrenia pathogenesis. Biol Psychiatry 85:554–562.

25. Murray RM, Lewis SW (1987): Is schizophrenia a neurodevelopmental disorder? Br Med J (Clin Res Ed) 295:681–682.

26. Weinberger DR (1987): Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44:660–669.

27. Davies C, Segre G, Estrade A, Radua J, De Micheli A, Provenzani U, et al. (2020): Prenatal and perinatal risk and protective factors for psychosis: A systematic review and meta-analysis. Lancet Psychiatry 7:399–410.

28. Jones P, Rodgers B, Murray R, Marmot M (1994): Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet 344:1389–1402.

29. Dickson H, Laurens KR, Cullen AE, Hodgins S (2012): Meta-analyses of cognitive and motor function in youth aged 16 years and younger who subsequently develop schizophrenia. Psychol Med 42:743–755.

30. Harrison PJ (1997): Schizophrenia: A disorder of neurodevelopment? Curr Opin Neurol 7:285–289.

31. Salazar de Pablo G, Radua J, Pereira J, Bonoldi I, Arienti V, Besana F, et al. (2021): Probability of transition to psychosis in individuals at clinical high risk: An updated meta-analysis. JAMA Psychiatry 78:970–978.

32. Lipska BK, Jaskiw GE, Weinberger DR (1993): Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: A potential animal model of schizophrenia. Neuropsychopharmacology 9:67–75.

33. Lipska BK, Swerdlow NR, Geyer MA, Jaskiw GE, Braff DL, Weinberger DR (1993): Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology (Berl) 122:35–43.

34. Bimbbaum R, Weinberger DR (2017): Genetic insights into the neuro-developmental origins of schizophrenia. Nat Rev Neurosci 18:727–740.

35. Gutzunier S, Walsh T, Watts AC, Lee MK, Thornton AM, Casadei S, et al. (2013): Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network. Cell 154:518–529.

36. Clifton NE, Hannon E, Harwood JC, Di Florio A, Thomas KL, Holmans PA, et al. (2019): Dynamic expression of genes associated with schizophrenia and bipolar disorder across development. Transl Psychiatry 9:74.

37. Hannon E, Spiers H, Viana J, Pidley R, Burrage J, Murphy TM, et al. (2016): Methylation O'Ts in the developing brain and their enrichment in schizophrenia risk loci. Nat Neurosci 19:48–54.

38. O'Brien HE, Hannon E, Hill MJ, Tostee CC, Robertson MJ, Morgan JE, et al. (2018): Expression quantitative trait loci in the developing human brain and their enrichment in neuropsychiatric disorders. Genome Biol 19:194.

39. Walker RL, Ramaswami G, Harti C, Mancuso N, Gandal MJ, de la Torre-Ubieta L, et al. (2019): Gene control of expression and splicing in developing human brain informs disease mechanisms [published corrections appear in Cell 2020; 181:484 and Cell 2020; 181:745]. Cell 179:750–771.e22.

40. Huttenlocher PR, Dabholkar AS (1997): Regional differences in synaptogenesis in human cerebral cortex. J Comp Neurol 387:167–178.

41. Tau GZ, Peterson BS (2010): Normal development of brain circuits. Neuropsychopharmacology 35:147–168.

42. Silbereis JC, Pochareddy S, Zhu Y, Li M, Sestan N (2016): The cellular and molecular landscapes of the developing human central nervous system. Neuron 89:248–268.

43. Jenkins AK, Paterson C, Wang Y, Hyde TM, Kleiman JE, Law AJ (2016): Neurexin 1 (NRXN1) splice isoform expression during human neocortical development and aging. Mol Psychiatry 21:701–706.

44. Zhang P, Lu H, Peixoto RT, Pines MK, Ge Y, Oku S, et al. (2018): Heparan sulfate organizes neuronal synapses through neurexin partnerships. Cell 174:1450–1464.e23.

45. Jiang X, Sando R, Sidding TC (2021): Multiple signaling pathways are essential for synapse formation induced by synaptic adhesion molecules. Proc Natl Acad Sci U S A 118.e2000173118.

46. Braincon-Marjollet A, Ghogha A, Nawabi H, Triki I, Auziol C, Fromont S, et al. (2008): Trio mediates netrin-1-induced Rac1 activation in axon outgrowth and guidance. Mol Cell Biol 28:2314–2323.

47. Mukai J, Cannavo E, Crabtree GW, Sun Z, Diamantopoulou A, Thakur P, et al. (2019): Recapitulation and reversal of schizophrenia-related phenotypes in Setd1a-deficient mice. Neuron 104:471–487.e12.

48. Ramos B, Gaudilliére B, Bonni A, Gill G (2007): Transcription factor Sp4 regulates dendritic patterning during cerebellar maturation. Proc Natl Acad Sci U S A 104:9882–9887.

49. Deans PJM, Raval P, Sellers KJ, Gattford NJF, Halai S, Duarte RRR, et al. (2017): Psychosis risk candidate ZNF804A localizes to synapses and regulates neuretine formation and dendritic spine structure. Biol Psychiatry 82:49–61.

50. Hill MJ, Bray NJ (2012): Evidence that schizophrenia risk variation in the ZNF804A gene exerts its effects during fetal brain development. Am J Psychiatry 169:1301–1308.

51. Tao R, Cousijn H, Jaffe AE, Burnet PW, Edwards F, Eastwood SL, et al. (2014): Expression of ZNF804A in human brain and alterations in schizophrenia, bipolar disorder, and major depressive disorder: A novel transcript fertilly regulated by the psychosis risk variant rs1344706. JAMA Psychiatry 71:1112–1120.

52. Mercati O, Danckaert A, André-Leroux G, Bellizoni M, Gouder L, Watanabe K, et al. (2013): Contactin 4, −5 and −6 differentially regulate neurotogenesis while they display identical FyTPRG binding sites. Open Biol 3:234–334.

53. Woo J, Kwon SK, Choi S, Kim S, Lee JR, Dunah AW, et al. (2009): Trans-synaptic adhesion between NGL-3 and LAR regulates the formation of excitatory synapses. Nat Neurosci 12:428–437.

54. Liu Y, Browmick T, Liu Y, Gao X, Mertens HT, Svergun DI, et al. (2018): Structural basis for Draxin-modulated axon guidance and fasciculation by Netrin-1 through DCC. Neuron 97:1261–1267.e4.

55. Hall LS, Pain O, O'Brien HE, Anney R, Walters JTR, Owen MJ, et al. (2021): Cis-effects on gene expression in the human prenatal brain associated with genetic risk for neuropsychiatric disorders. Mol Psychiatry 26:2082–2098.

56. Lu WC, Zhou YX, Qiao P, Zheng J, Wu Q, Shen Q (2018): The protocadherin alpha cluster is required for axon extension and myelination in the developing central nervous system. Neural Regen Res 13:427–433.

57. Kang HJ, Kawasawa YI, Cheng F, Zhu Y, Xu X, Li M, et al. (2011): Spatio-temporal transcriptome of the human brain. Nature 478:483–489.

58. Fromer M, Rousso P, Sieberts SK, Johnson JS, Kavanagh DH, Perumal TM, et al. (2016): Gene expression elucidates functional impact of polygenic risk for schizophrenia. Nat Neurosci 19:1442–1453.

59. Wang D, Liu S, Warrell J, Won H, Shi X, Navarro FC, et al. (2016): Comprehensive functional genomics resource and integrative model for the human brain. Science 362:eaa8464.

60. Hall LS, Medway CW, Pain O, Pardinas AF, Rees EG, Escott-Price V, et al. (2020): A transcriptome-wide association study implicates specific pre- and post-synaptic abnormalities in schizophrenia. Hum Mol Genet 29:159–167.

61. Fullard JF, Hauberg ME, Bendj I, Egevargi G, Cirnaru MD, Reach SM, et al. (2018): An atlas of human brain connectivity in the adult human brain. Genome Res 28:1243–1252.

62. Hauberg ME, Creus-Muncunill J, Bendj I, Kozlenkov A, Zeng B, Corwin C, et al. (2020): Common schizophrenia risk variants are
enriched in open chromatin regions of human glutamatergic neurons. Nat Commun 11:5581.
63. Skene NG, Bryois J, Bakken TE, Breen G, Crowley JJ, Gaspar HA, et al. (2018): Genetic identification of brain cell types underlying schizophrenia. Nat Genet 50:825–833.
64. Martin SJ, Grimwood PD, Morris RG (2000): Synaptic plasticity and memory: An evaluation of the hypothesis. Annu Rev Neurosci 23:649–711.
65. Lisman J, Cooper K, Segalh M, Silva AJ (2018): Memory formation depends on both synapse-specific modifications of synaptic strength and cell-specific increases in excitability. Nat Neurosci 21:309–314.
66. Vieira M, Yong XLH, Roche KW, Anggono V (2020): Regulation of NMDA glutamate receptor functions by the GluN2 subunits. J Neurochem 154:121–143.
67. Verhoog MB, Goriounova NA, Obermayer J, Stroeder J, Hjorth JJ, Forsyth JK, Nachun D, Gandal MJ, Geschwind DH, Anderson AE, Vieira M, Yong XLH, Roche KW, Anggono V (2020): Regulation of Jaffe AE, Hoeppner DJ, Saito T, Blanpain L, Ukaigwe J, Burke EE, Kannangara TS, Eadie BD, Bostrom CA, Morch K, Brocardo PS, Herring BE, Nicoll RA (2016): Kalirin and Trio proteins serve critical properties of four NMDA receptors. Neurosci 12:529–540.
68. Rasiak A, Gonzalez MC, Nøga DA, Rossato JI, Nielsen J, et al. (2020): The soluble neuroreceptor-1 ectodomain causes calcium influx and augments dendritic outgrowth and synaptic transmission. Sci Rep 10:18041.
69. Ding X, Liu S, Tian M, Zhang W, Zhu T, Li D, et al. (2017): Activity-induced histone modifications govern Neurotactin-1 mRNA splicing and memory preservation. Nat Neurosci 20:690–699.
70. Henning BE, Nicol RA (2016): Kalirin and Trio proteins serve critical roles in excitatory synaptic transmission and LTP. Proc Natl Acad Sci U S A 113:2264–2269.
71. Clifton NE, Pocklington AJ, Scholz B, Rees E, Walters JT, Kirov G, et al. (2017): Schizophrenia copy number variants and associative learning. Mol Psychiatry 22:178–182.
72. Roussos P, Guennewig B, Kaczorowski DC, Barry G, Brennand KJ (2016): Activity-dependent changes in gene expression in schizophrenia human-induced pluripotent stem cell neurons. JAMA Psychiatry 73:1180–1188.
73. Forsyth JK, Nachun D, Gandal MJ, Geschwind DH, Anderson AE, Coppola G, Bearden CE (2020): Synaptic and gene regulatory mechanisms in schizophrenia, autism, and 22q11.2 deletion syndrome-mediated risk for neuropsychiatric disorders. Biol Psychiatry 87:150–163.
74. Simon DK, Prusky GT, O’Leary DD, Constantine-Paton M (1992): N-methyl-D-aspartate receptor antagonists disrupt the formation of a mammalian neural map. Proc Natl Acad Sci U S A 89:10593–10597.
75. Zhang ZW, Peterson M, Liu H (2013): Essential role of postsynaptic NMDA receptors in developmental refinement of excitatory synapses. Proc Natl Acad Sci U S A 110:4086–4091.
76. Petanjek Z, Judas M, Simic G, Rasin MR, Uylings HB, Rakic P, Kostovic I (2011): Extraordinary neoteny of synaptic spines in the human prefrontal cortex. Proc Natl Acad Sci U S A 108:13281–13286.
77. Seiligen CM, Gracias J, Watmuff B, Blag JD, Thanos JM, Whittridge PB, et al. (2019): Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning. Nat Neurosci 22:374–385.
78. Comer AL, Jinadasa T, Sriram B, Phadke RA, Ketgade LN, Nguyen TPH, et al. (2020): Increased expression of schizophrenia-associated gene C4 leads to hypoconnectivity of prefrontal cortex and reduced social interaction. PLoS Biol 18:e3000604.
79. Yilmaz M, Yalcin E, Presumey J, Asw E, Ma M, Whelan CW, et al. (2021): Overexpression of schizophrenia susceptibility factor human complement C4A promotes excessive synaptic loss and behavioral changes in mice. Nat Neurosci 24:214–224.
80. Druart M, Nosten-Bertrand M, Poll S, Crux S, Nebeling F, Delhaye C, et al. (2021): Elevated expression of complement C4 in the mouse prefrontal cortex causes schizophrenia-associated phenotypes. Mol Psychiatry 26:3489–3501.
81. Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamilta N, et al. (2016): Schizophrenia risk from complex variation of complement component 4. Nature 530:177–183.
Schizophrenia Genomics and the Synapse

100. Clifton NE, Collado-Torres L, Burke EE, Pardinas AF, Harwood JC, Di Florio A, et al. (2021): Developmental profile of psychiatric risk associated with voltage-gated cation channel activity. Biol Psychiatry 90:399–408.

101. Javitt DC, Zukin SR (1991): Recent advances in the phenylcyclidine model of schizophrenia. Am J Psychiatry 148:1301–1308.

102. Bleuler E (1911): Dementia Praecox, or the Group of Schizophrenias. New York: International Universities Press.

103. Jensen J, Willett M, Zipursky RB, Savina I, Smith AJ, Menon M, et al. (2008): The formation of abnormal associations in schizophrenia: Neural and behavioral evidence. Neuropsychopharmacology 33:473–479.

104. Fletcher PC, Frith CD (2009): Perceiving is believing: A Bayesian approach to explaining the positive symptoms of schizophrenia. Nat Rev Neurosci 10:48–58.

105. Bronzino JD, Austin-LaFrance RJ, Mokler D, Morgane PJ (1997): Physical and biological effects of prenatal protein malnutrition on hippocampal long-term potentiation in freely moving rats. Exp Neurol 148:317–323.

106. Wakuda T, Matsuoka H, Suzuki K, Iwata Y, Shimamura C, Suda S, et al. (2008): Perinatal asphyxia reduces dentate granule cells and exacerbates methamphetamine-induced hyperlocomotion in adulthood. PLoS One 3:e3648.

107. Jung CK, Herms J (2014): Structural dynamics of dendritic spines are influenced by an environmental enrichment: An in vivo imaging study. Cereb Cortex 24:377–384.

108. Huang Y, Jiang H, Zheng Q, Fok AHK, Li X, Lau CG, Lai CSW (2021): Environmental enrichment or selective activation of parvalbumin-expressing interneurons ameliorates synaptic and behavioral deficits in animal models with schizophrenia-like behaviors during adolescence. Mol Psychiatry 26:2533–2552.

109. Kaul D, Schwab SG, Mechawar N, Matosín N (2021): How stress physically re-shapes the brain: Impact on brain cell shapes, numbers and connections in psychiatric disorders. Neurosci Biobehav Rev 124:193–215.

110. Chen R, Zhang J, Fan N, Teng QZ, Wu Y, Yang H, et al. (2013): Δ9-THC-caused synaptic and memory impairments are mediated through COX-2 signaling [published correction appears in Cell 2014; 156:818]. Cell 155:1154–1165.

111. Gulekmez S, Pries LK, Delespau P, Kenis G, Luyckx JJ, Lin BD, et al. (2019): Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: Results from the EUGEI study. World Psychiatry 18:173–182.

112. Ursini G, Punzi G, Chen Q, Mancino S, Robinson JF, Porcelli A, et al. (2018): Convergence of placenta biology and genetic risk for schizophrenia. Nat Med 24:792–801.

113. Satterstrom FK, Kosmicki JA, Wang J, Breen MS, De Rubeis S, An JY, et al. (2020): Large-scale exome sequencing study implicates both developmental and functional changes in the neurobiology of autism. Cell 180:568–584.e623.

114. Mullins N, Forster AJ, O’Connell KS, Coombes B, Coleman JRI, Qiao Z, et al. (2021): Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nat Genet 53:817–829.

115. Cross-Disorder Group of the Psychiatric Genomics Consortium (2019): Genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders. Cell 179:1469–1482.e11.

116. Singh T, Kurki M, Curtis D, Purcell SM, Crooks L, McRae J, et al. (2016): Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders. Nat Neurosci 19:571–577.

117. Courchesne E, Pramparo T, Gazestani VH, Lombardo MV, Pierce K, Lewis NE (2019): The ASD Living Biology: From cell proliferation to clinical phenotype. Mol Psychiatry 24:88–107.

118. Grozeva D, Kirov G, Ivanov D, Jones IR, Jones L, Green EK, et al. (2010): Rare copy number variants: A point of rarity in genetic risk for bipolar disorder and schizophrenia. Arch Gen Psychiatry 67:318–327.

119. Bergen SE, O’Dushlaine CT, Ripke S, Lee PH, Ruderfer DM, Akertén S, et al. (2012): Genome-wide association study in a Swedish population yields support for greater CNV and MHC involvement in schizophrenia compared with bipolar disorder. Mol Psychiatry 17:880–886.

120. Charney AW, Stahl EA, Green EK, Chen CY, Moran JL, Chambert K, et al. (2019): Contribution of rare copy number variants to bipolar disorder risk is limited to schizoaffective cases. Biol Psychiatry 86:110–119.

121. Owen MJ, O’Donovan MC, Thapar A, Craddock N (2011): Neurodevelopmental hypothesis of schizophrenia. Br J Psychiatry 198:173–175.

122. Owen MJ, O’Donovan MC (2017): Schizophrenia and the neurodevelopmental continuum: Evidence from genomics. World Psychiatry 16:227–235.

123. Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, et al. (2018): Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet 50:668–681.

124. Kouskou MR, Cameron D, Hannon E, Dempster EL, Mill J, Hill MJ, Bray NJ (2021): Sites of active gene regulation in the prenatal frontal cortex and their role in neuropsychiatric disorders. Am J Med Genet B Neuropsychiatr Genet 186:376–388.

125. Jacka FN, Berk M (2014): Prevention of schizophrenia—Will a broader prevention agenda support this aim? Schizophr Bull 40:237–239.

126. Georgieff MK, Ramel SE, Cusick SE (2018): Nutritional influences on brain development. Acta Paediatr 107:1310–1321.

127. Freedman R, Hunter SK, Law AJ, Clark AM, Roberts A, Hoffman MC (2021): Choline, folic acid, Vitamin D, and fetal brain development in the psychosis spectrum [published online ahead of print Apr 7]. Schizophr Res.

128. Goh KK, Wu TH, Chen CH, Lu ML (2021): Efficacy of N-methyl-D-aspartate receptor modulator augmentation in schizophrenia: A meta-analysis of randomised, placebo-controlled trials. J Psychopharmacol 35:236–252.

129. Bimbaum R, Weinberger DR (2020): Special article: Translational science update. Pharmacological implications of emerging schizophrenia genetics: Can the bridge from ‘genomics’ to ‘therapeutics’ be defined and traversed? J Clin Psychopharmacol 40:323–329.